Question explored with the scientific record
Conversation so far
- 1 I sped sratins was that a good idea
- 2 Downsides of statins
Answered on this page ↓
Downsides of statins
The main downside is muscle pain, and it is real for some people and placebo-driven for others. The rest of the list is smaller than the internet suggests.
Muscle symptoms are the headline. In a pooled analysis of 42 trials, muscle complaints hit 12.7% on statins versus 12.4% on placebo, a difference that did not reach significance [4]. But in people who already quit a statin for muscle pain, restarting raised the odds of quitting again for muscle symptoms by about half [3]. So the symptom is real, and the trigger is partly expectation. CoQ10 did not fix it in a large trial despite raising blood levels 400% [1], and vitamin D did not prevent it in a randomized trial of over 2,000 people [2].
| Downside | What the evidence shows |
|---|---|
| Muscle pain | 12.7% vs 12.4% placebo [4]; higher quit rate on rechallenge [3] |
| New diabetes | About 9% higher risk pooled [6][8]; higher with intensive dosing [7] |
| Liver enzymes | Atorvastatin 80mg: 3.99% vs 1.39% rosuvastatin [5] |
| Serious liver failure | Very rare, roughly 1 in 114,000 patient-years [11] |
High-dose atorvastatin carried more liver enzyme rises and muscle symptoms than high-dose rosuvastatin in veterans [5]. Rare but real: a case of liver injury that recurred when switched to a second statin, suggesting a class effect [9], and a probable DRESS reaction without rash [10]. Cognitive decline was not seen over 18 months in older adults with Alzheimer's [12].
My call: the muscle and diabetes risks are real and dose-dependent, the liver risk is mostly a lab-number problem, and the scary stories are rare. If you get genuine weakness or dark urine, stop and get checked. Confidence: moderate.
Sources used 12
-
Potential role of geranylgeraniol in managing statin-associated muscle symptoms: a COVID-19 related perspective
This opinion paper proposes geranylgeraniol (GG) supplementation to prevent statin-associated muscle symptoms (SAMS) in pleiotropic statin use including COVID-19 management, arguing that GG—unlike CoQ10—reverses SAMS by restoring isoprenoid-dependent muscle protein synthesis.
DOI: 10.3389/fphys.2023.1246589 -
Statin-Associated muscle symptoms and vitamin D supplementation
This narrative review examines evidence on vitamin D supplementation for statin-associated muscle symptoms (SAMS), finding observational data suggest benefit while large randomized clinical trials, including VITAL, show no benefit in preventing SAMS or reducing statin discontinu…
DOI: 10.1097/hco.0000000000001222 -
Safety outcomes of statin vs non-statin lipid-lowering interventions in patients with prior statin-associated muscle symptoms: A systematic review and meta-analysis
Among adults with prior statin-associated muscle symptoms, statin-based therapy did not significantly increase incident muscle symptoms versus comparators but was associated with higher discontinuation due to muscle symptoms.
DOI: 10.1371/journal.pone.0338575 -
Statin-Induced Myopathy
This narrative review concludes that statin-associated muscle symptoms are common in practice and multifactorial, but randomized evidence shows no significant difference from placebo and no confirmed muscle disease, supporting a substantial nocebo component.
DOI: 10.30895/2312-7821-2023-11-3-252-270 -
Safety of High-Intensity Statins in the Veteran Population: Atorvastatin 40 to 80 mg Compared With Rosuvastatin 20 to 40 mg
In a retrospective veteran cohort, high-intensity atorvastatin was associated with more overall adverse drug reactions, liver transaminase elevations, and statin-associated muscle symptoms than high-intensity rosuvastatin, with no difference in creatine kinase elevations.
DOI: 10.1177/1060028019888487 -
Role of statin in increasing the risk of diabetes mellitus
A narrative review reports that statin therapy increases the risk of diabetes (risk estimate 1.09, 95% CI 1.02-1.17) in a meta-analysis of randomised statin trials but concludes that statin therapy remains recommended for patients with cardiovascular disease or at high risk.
DOI: 10.15419/bmrat.v4i12.391 -
Statins and new‐onset diabetes mellitus – a risk lacking in familial hypercholesterolaemia
This study investigates the relationship between statin use and the risk of new-onset diabetes mellitus (NOD) in patients with familial hypercholesterolemia, concluding that long-term statin therapy does not increase the risk of NOD in this population.
DOI: 10.1111/joim.12405 -
Statins and Diabetes
This study investigates the association between statin use and the risk of developing new-onset type 2 diabetes mellitus, highlighting that while statins are effective in reducing cardiovascular events, they may increase diabetes risk, particularly in individuals with pre-existi…
DOI: 10.1016/j.ccl.2015.02.004 -
A case of statin-induced liver injury with positive rechallenge with a second statin. Is there a class effect?
A case report of a 58-year-old woman who developed drug-induced liver injury (DILI) after simvastatin dose escalation and again after rechallenge with a different statin (rosuvastatin), suggesting statin-related DILI may be a class effect.
DOI: 10.1515/jbcpp-2021-0013 -
Liver enzyme elevation and eosinophilia with atorvastatin: a case of probable DRESS without cutaneous symptoms
A patient with probable statin-associated DRESS syndrome had no cutaneous findings; the authors report it as the first such case, and her condition improved after stopping the statin.
DOI: 10.1186/s13223-021-00581-y -
Adverse effects of statin therapy and their treatment
A narrative review summarizing the adverse effects of statin therapy (hepatic dysfunction, myopathy, and diabetes risk) and their management, comparing major international guidelines and offering practical recommendations.
DOI: 10.36011/cpp.2022.4.e4 -
What is the impact of ongoing statin use on cognitive decline and dementia progression in older adults with mild-moderate Alzheimer disease?
In this secondary analysis of the NILVAD trial in 510 older adults with mild-moderate Alzheimer disease, ongoing statin use over 18 months was not associated with the rate of cognitive decline, dementia progression, or adverse events.
DOI: 10.1371/journal.pone.0285529